Femasys Stock
Femasys Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- United States
- CEO
- Kathy Lee-Sepsick
- Employees
- 53
- Market cap
- $14 M
- IPO
- 18/06/2021
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial…
Femasys stock: price history
1D
-5.2%
1W
-17.5%
1M
-35.0%
6M
-80.5%
YTD
-85.7%
1Y
-88.9%
2Y
-93.3%
5Y
-98.8%
10Y
–
Next earnings date
Next earnings date
17/11/2026 (in 31 days)
Volatility around earnings
~15% weaker price swings than usual
Ask the agents about Femasys
Analyst assessment of Femasys
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 18/08/2026
Femasys stock metrics
P/E
-0.36
P/B
1.37
EV/EBITDA
-1.78
RETURN ON EQUITY
-110.9%
NET MARGIN
-1,346.8%
DEBT/EQUITY
1.19
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.7%
FLOAT SHARES
7,347,579
AVG. DAILY VOLUME (30D)
89,301
Insider transactions (SEC)
Lee-Sepsick Kathy
Elefant Dov
Canning John Charles
Sipos Jeremy Alexander
Mifek Jeffrey Gerald
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Femasys stock
What does Femasys do?
Femasys Inc. is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in United States.
The CEO is Kathy Lee-Sepsick, the company employs around 53 people.
The IPO was on 18/06/2021; the stock trades on NASDAQ under the ticker FEMY.
What do analysts say about Femasys stock?
6 analysts rate the stock, the consensus is Buy (as of 18/08/2026).
This is an external assessment, not a statement by Market Jury.
When does Femasys report next?
The next earnings date is 17/11/2026.
Around past earnings, price swings were roughly -15% stronger than usual.
Does Femasys pay a dividend?
No, Femasys currently does not pay a dividend.
Which stocks are comparable to Femasys?
Comparable stocks include Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International, Cooper Companies and Avantor.
How can I get Femasys stock analyzed?
Clicking "Analyze stock" lets five strategies assess Femasys against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.